Which peptides come in pill form?
FAQAmong this site's compounds, only semaglutide has an FDA-approved pill, as three tablet products. Oral forms of hexarelin, GHRP-6, AOD-9604 and glutathione have human trials. On October 7, 2026, Prof. Peptide counted capsule or tablet products at 30 of 71 vendor catalogs, most of them compounds with no human oral data.
On this page
Oral forms, compound by compound
| Compound | Form | Status of that form | Evidence level |
|---|---|---|---|
| Semaglutide | tablet | FDA-approved product (three) | Human RCT |
| Hexarelin | oral | human trials | Human Observational |
| GHRP-6 | capsule | human trials | Human Observational |
| GHRP-2 | oral | human trials | Human Observational |
| AOD-9604 | capsule, tablet | human trials (safety reported); sold by 1 vendor | Human RCT |
| Glutathione | capsule, sublingual | human trials | Human RCT |
| NAD+ (not a peptide) | oral | human trials | Human RCT |
| MK-677 (not a peptide) | capsule | human trials; sold by 8 vendors | Human RCT |
| BPC-157 | capsule, tablet | animal only; one human trial, no results; sold by 21 vendors | Animal Model |
| KPV | capsule | animal only; sold by 7 vendors | Animal Model |
| Thymosin Alpha-1 | capsule | animal only; sold by 2 vendors | Animal Model |
| 5-Amino-1MQ (not a peptide) | capsule | animal only; sold by 19 vendors | Animal Model |
| Tirzepatide | tablet | animal only (dogs) | Animal Model |
| PT-141 | oral | animal only (dogs) | Animal Model |
| DSIP | oral | in vitro only | In Vitro |
| GHK-Cu | capsule | research market only; sold by 7 vendors | none found |
| TB-500 | capsule | research market only; sold by 3 vendors | none found |
| Epitalon | capsule | research market only; sold by 1 vendor | none found |
The status describes the oral form only; the evidence badge on each compound's profile covers every route and is often an injection study. "Research market only" means listed for sale with no study of that form found. A vendor count says what is listed, not that any product is absorbed.
What the human oral trials found
The approved semaglutide tablets reach the blood at an estimated 0.4–2% by label, and per the OASIS 4 paper, oral semaglutide 25 mg produced a 13.6% mean weight loss over 64 weeks against 2.2% on placebo. Hexarelin by mouth produced about 0.3% of the growth-hormone response of an intravenous dose in a 1994 study, against 77% for a subcutaneous dose. The AOD-9604 oral trials report safety only, and the glutathione trials disagree with each other.
For the adverse events reported at the semaglutide tablet doses, see semaglutide side effects.
What the research market sells as pills
Capsules and tablets were the most common non-injectable format in Prof. Peptide's October 7, 2026 count, listed at 30 of 71 vendor catalogs. The most widely listed were BPC-157 (21 vendors), 5-amino-1MQ (19), MK-677 (8), BPC-157 with TB-500 (8), KPV (7) and GHK-Cu (7). Orforglipron, the active ingredient of the approved non-peptide pill Foundayo, was listed as capsules or tablets at 4. None of these research-market products is an approved drug, and for most of the peptides among them no study of the oral form in people exists.
Approved oral peptides outside this site's compound list
Desmopressin (DDAVP tablets, Desmoda solution), octreotide (Mycapssa capsules), linaclotide (Linzess) and plecanatide (Trulance) are FDA-approved oral peptide products. The last two act inside the intestine and are minimally absorbed by design.
Why the absorption gap is so large, with each label's figure, is set out in peptide pills vs nasal sprays vs injections.
Sources
Primary
- Rybelsus and Ozempic tablets and Wegovy prescribing information, DailyMed sets 27f15fac-7d98-4114-a2ec-92494a91da98 and ee06186f-2aa3-4990-a760-757579d8f77b → — the approved semaglutide tablets and their bioavailability
- OASIS 4. N Engl J Med 2025 (PMID 40934115) → — −13.6% vs −2.2% at week 64
- Ghigo E et al. J Clin Endocrinol Metab 1994 (PMID 8126144) → — hexarelin oral and subcutaneous bioavailability
- Frieboes RM et al. J Neuroendocrinol 1999 (PMID 10336729) → — GHRP-6 oral, intranasal and sublingual
- Long-term oral GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab 2003 (PMID 14513874) → — GHRP-2 given orally in people
- Stier H, Vos E, Kenley D. J Endocrinol Metab 2013 → — AOD-9604 oral trials, safety results
- Richie JP Jr et al. Eur J Nutr 2015 (PMID 24791752); Witschi A et al. Eur J Clin Pharmacol 1992 (PMID 1362956) → — the two conflicting oral glutathione studies
- Kornilov SA et al. Geroscience 2026 (PMID 42530810) → — oral NAD+ trial
- Nass R et al. Ann Intern Med 2008 (PMID 18981485) → — MK-677 two-year oral trial
- ClinicalTrials.gov NCT02637284; Klicek R et al. J Pharmacol Sci 2008 (PMID 18818478) → — BPC-157: the oral trial with no results, and the rat oral study
- Dalmasso G et al. Gastroenterology 2008 (PMID 18061177) → — KPV in drinking water, mice
- Im S et al. Pharmaceutics 2026 (PMID 42514904) → — oral tirzepatide in beagle dogs
- Augustijns P et al. Drug Metab Dispos 1995 (PMID 8689946) → — DSIP across intestinal cell monolayers
For the other common questions about research peptides, see the questions hub.
Related questions
Research use only. Not medical advice.